@article{10263516d4634a7fb00b706eae7ec3e2,
title = "Adherence to guideline recommendations for multimodality treatment of patients with pT2–3 M0 non-urothelial carcinoma of the urinary bladder: Temporal trends and survival outcomes: International Journal of Urology",
abstract = "Objectives: To analyze contemporary multimodality treatment rates, defined as radical cystectomy plus chemotherapy and/or radiotherapy, for pT2–3 any N-stage M0 non-urothelial carcinoma of urinary bladder patients. Additionally, we tested for the effect of multimodality treatment versus radical cystectomy alone on cancer-specific mortality. Methods: Within the Surveillance, Epidemiology and End Results database (2004–2015), 887 pT2–3 any N-stage M0 non-urothelial carcinoma of urinary bladder patients treated with radical cystectomy were identified. Kaplan–Meier plots, and univariable and multivariable Cox regression analyses focused on cancer-specific mortality rates. Results: Squamous cell carcinoma was recorded in 499 (56.3%) patients, neuroendocrine carcinoma in 246 (27.7%) and adenocarcinoma in 142 (16.0%). The highest proportion of multimodality treatment patients was recorded in neuroendocrine carcinoma (69.1%), relative to adenocarcinoma (34.5%) and squamous cell carcinoma (26.4%). A statistically significant annual increase was recorded in multimodality treatment rates in neuroendocrine carcinoma patients (46.7–74.2%, P ",
keywords = "adenocarcinoma, combined modality therapy, neuroendocrine carcinoma, squamous cell carcinoma, urinary bladder neoplasms, antineoplastic agent, adult, aged, Article, bladder carcinoma, cancer chemotherapy, cancer mortality, cancer radiotherapy, cancer survival, cohort analysis, cystectomy, female, human, major clinical study, male, multimodality cancer therapy, practice guideline, priority journal",
author = "F.A. Mistretta and C. Negrean-Dzyuba and C. Palumbo and A. Pecoraro and S. Knipper and Z. Tian and G. Musi and E. Montanari and P. Perrotte and A. Briganti and S.F. Shariat and F. Saad and {de Cobelli}, O. and P.I. Karakiewicz",
note = "Cited By :2 Export Date: 19 March 2021 CODEN: IJURF Correspondence Address: Mistretta, F.A.; Cancer Prognostics and Health Outcomes Unit, Canada; email: mistretta.francesco.a@gmail.com References: Alanee, S., Alvarado-Cabrero, I., Murugan, P., Update of the International Consultation on Urological Diseases on bladder cancer 2018: non-urothelial cancers of the urinary bladder (2019) World J. Urol., 37, pp. 107-114; Moschini, M., Dell{\textquoteright}Oglio, P., Luciano{\textquoteright}, R., Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy (2017) Urol. Oncol., 35, pp. 335-341; Kassouf, W., Spiess, P.E., Siefker-Radtke, A., Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience (2007) Cancer, 110, pp. 764-769; Monn, M.F., Kaimakliotis, H.Z., Pedrosa, J.A., Contemporary bladder cancer: variant histology may be a significant driver of disease (2015) Urol. Oncol., 33, pp. 18.e15-20; Soave, A., Schmidt, S., Dahlem, R., Does the extent of variant histology affect oncological outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy? (2015) Urol. Oncol., 33, pp. 21.e21-9; Xylinas, E., Rink, M., Robinson, B.D., Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy (2013) Eur. J. Cancer., 49, pp. 1889-1897; Izard, J.P., Siemens, D.R., Mackillop, W.J., Outcomes of squamous histology in bladder cancer: a population-based study (2015) Urol. Oncol., 33, pp. 425.e7-13; Zaffuto, E., Gazdovich, S., Leyh-Bannurah, S.R., Contemporary rates of pathological features and mortality for adenocarcinoma of the urinary bladder in the USA (2017) Int. J. Urol., 24, pp. 117-123; (2018) Clinical Practice Guidelines in Oncology (NCCN Guidelines). Bladder cancer, version 1.2019, , https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf, [Cited Dec 2018.] Available URL from; Zargar-Shoshtari, K., Sverrisson, E.F., Sharma, P., Clinical outcomes after neoadjuvant chemotherapy and radical cystectomy in the presence of urothelial carcinoma of the bladder with squamous or glandular differentiation (2016) Clin. Genitourin. Cancer, 14, pp. 82-88; Pokuri, V.K., Syed, J.R., Yang, Z., Predictors of complete pathologic response (pT0) to neoadjuvant chemotherapy in muscle-invasive bladder carcinoma (2016) Clin. Genitourin. Cancer, 14, pp. e59-65; Lynch, S.P., Shen, Y., Kamat, A., Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center (2013) Eur. Urol., 64, pp. 307-313; SEER cancer statistics review, , https://seer.cancer.gov/data-software/documentation/seerstat/nov2016/2017, [Cited Dec 2018.] Available from URL; Niu, Q., Lu, Y., Xu, S., Clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: a population-based study (2018) Cancer Manag. Res., 10, pp. 4479-4489; Patel, S.G., Weiner, A.B., Keegan, K., Morgan, T., Oncologic outcomes in patients with nonurothelial bladder cancer (2018) Indian J. Urol., 34, pp. 39-44; Vetterlein, M.W., Wankowicz, S.A.M., Seisen, T., Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology (2017) Cancer, 123, pp. 4346-4355; Mazzone, E., Knipper, S., Mistretta, F.A., Is neoadjuvant chemotherapy for pT2 bladder cancer associated with a survival benefit in a population-based analysis? (2019) Cancer Epidemiol., 58, pp. 83-88; Scosyrev, E., Messing, E.M., Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? (2011) BJU Int., 108, p. 700",
year = "2020",
doi = "10.1111/iju.14206",
language = "English",
volume = "27",
pages = "402--407",
journal = "Int. J. Urol.",
issn = "0919-8172",
publisher = "Blackwell Publishing",
number = "5",
}